Sponga Sandro, Di Mauro Michele, Malvindi Pietro G, Paparella Domenico, Murana Giacomo, Pacini Davide, Weltert Luca, De Paulis Ruggero, Cappabianca Giangiuseppe, Beghi Cesare, De Vincentiis Carlo, Parolari Alessandro, Messina Antonio, Troise Giovanni, Salsano Antonio, Santini Francesco, Pierri Michele D, Di Eusanio Marco, Maselli Daniele, Actis Dato Guglielmo, Centofanti Paolo, Mancuso Samuel, Rinaldi Mauro, Cagnoni Giuseppe, Antona Carlo, Picichè Marco, Salvador Loris, Cugola Diego, Galletti Lorenzo, Pozzoli Alberto, De Bonis Michele, Lorusso Roberto, Bortolotti Uberto, Livi Ugolino
Cardiothoracic Department, University Hospital of Udine, DAME Udine Medical School, Udine, Italy.
Cardiac Surgery, University "G. D'Annunzio" Chieti-Pescara, Chieti, Italy.
Eur J Cardiothorac Surg. 2020 Oct 1;58(4):839-846. doi: 10.1093/ejcts/ezaa136.
Endocarditis after the Bentall procedure is a severe disease often complicated by a pseudoaneurysm or mediastinitis. Reoperation is challenging but conservative therapy is not effective. The aim of this study was to assess short- and midterm outcomes of patients reoperated on for Bentall-related endocarditis.
Seventy-three patients with Bentall procedure-related endocarditis were recorded in the Italian registry. The mean age was 57 ± 14 years and 92% were men; preoperative comorbidities included hypertension (45%), diabetes (12%) and renal failure (11%). The logistic EuroSCORE was 25%; the EuroSCORE II was 8%.
Preoperatively, 12% of the patients were in septic shock; left ventricular-aortic discontinuity was present in 63% and mitral valve involvement occurred in 12%. The most common pathogens were Staphylococcus aureus (22%) and Streptococci (14%). Reoperations after a median interval of 30 months (1-221 months) included a repeat Bentall with a bioconduit (41%), a composite mechanical (33%) or biological valved conduit (19%) and a homograft (6%). In 1 patient, a heart transplant was required (1%); in 12%, a mitral valve procedure was needed. The hospital mortality rate was 15%. The postoperative course was complicated by renal failure (19%), major bleeding (14%), pulmonary failure (14%), sepsis (11%) and multiorgan failure (8%). At multivariate analysis, urgent surgery was a risk factor for early death [hazard ratio 20.5 (1.9-219)]. Survival at 5 and 8 years was 75 ± 6% and 71 ± 7%, with 3 cases of endocarditis relapse.
Surgery is effective in treating endocarditis following the Bentall procedure although it is associated with high perioperative mortality and morbidity rates. Endocarditis relapse seems to be uncommon.
Bentall手术后的心内膜炎是一种严重疾病,常并发假性动脉瘤或纵隔炎。再次手术具有挑战性,但保守治疗无效。本研究的目的是评估因Bentall相关心内膜炎接受再次手术患者的短期和中期结局。
意大利登记处记录了73例与Bentall手术相关的心内膜炎患者。平均年龄为57±14岁,92%为男性;术前合并症包括高血压(45%)、糖尿病(12%)和肾衰竭(11%)。逻辑欧洲心脏手术风险评估系统(logistic EuroSCORE)为25%;欧洲心脏手术风险评估系统二代(EuroSCORE II)为8%。
术前,12%的患者处于感染性休克;63%存在左心室-主动脉连续性中断,12%累及二尖瓣。最常见的病原体是金黄色葡萄球菌(22%)和链球菌(14%)。中位间隔30个月(1-221个月)后的再次手术包括使用生物管道的重复Bentall手术(41%)、复合机械(33%)或带生物瓣膜管道(19%)以及同种异体移植物(6%)。1例患者需要进行心脏移植(1%);12%的患者需要进行二尖瓣手术。医院死亡率为15%。术后病程并发肾衰竭(19%)、大出血(14%)、肺功能衰竭(14%)、脓毒症(11%)和多器官功能衰竭(8%)。多因素分析显示,急诊手术是早期死亡的危险因素[风险比20.5(1.9-219)]。5年和8年生存率分别为75±6%和71±7%,有3例心内膜炎复发。
手术治疗Bentall手术后的心内膜炎有效,尽管围手术期死亡率和发病率较高。心内膜炎复发似乎并不常见。